VIDEO: Health disparities in non-Hodgkin lymphoma care

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Unfortunately, we recognize that healthcare disparities are a persistent and pervasive problem in this country, to say nothing of the global community. We recognize that, for instance, when you look at the outcomes for patients with relapsed or refractory large cell lymphoma being treated with CAR T-cell, we see that there are indeed different outcomes on the basis of race, ethnicity, and socioeconomic status.

There's literature to suggest that patients who are of lower SES status have worse outcomes, literature to say that patients of color have both more toxicity and less activity when treated with CAR T-cell therapy. This is not because of underlying biology of race or ethnicity, but rather it is better understood as a reflection of healthcare disparities that such patients are being referred at later lines of therapy with greater burdens of disease and thus at higher risk both for toxicity from treatment as well as adverse outcomes with those treatments.